Caribou Biosciences, Inc. 8-K

What Happened
Caribou Biosciences, Inc. (CRBU) filed a Form 8-K on March 31, 2026 (Items 7.01 and 8.01) to announce that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011, its allogeneic anti-BCMA CAR‑T cell therapy, for the treatment of relapsed or refractory multiple myeloma (r/r MM). The company said CB-011 is currently being evaluated in the ongoing CaMMouflage Phase 1 clinical trial and furnished a press release (Exhibit 99.1) with the filing.

Key Details

• RMAT designation granted by FDA on March 31, 2026 for CB-011 for r/r MM.
• CB-011 is an allogeneic (off-the-shelf) anti-BCMA CAR‑T cell therapy in the CaMMouflage Phase 1 trial.
• Announcement made via Form 8-K (Items 7.01 and 8.01); press release included as Exhibit 99.1.
• The filing did not disclose financial results or other corporate changes.

Why It Matters
RMAT designation is an FDA pathway intended to accelerate development and review of promising regenerative medicines for serious conditions. For investors, this is a regulatory milestone that can increase the program’s regulatory support and potentially enable expedited review interactions (e.g., more FDA engagement and eligibility for accelerated approval or priority pathways), but it is not an approval and does not guarantee commercial success. Because CB-011 is still in Phase 1, the next material events for investors will be clinical trial readouts, additional regulatory milestones, and any partnering or commercialization plans.